Patents Assigned to Mochida Pharmaceutical Co., Ltd.
  • Publication number: 20200308136
    Abstract: Provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea which are useful as bulk pharmaceutical crystals. Also provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea having excellent TrkA inhibitory effect, medicines and medicinal composition containing these crystals, and a method for producing these crystals.
    Type: Application
    Filed: September 13, 2018
    Publication date: October 1, 2020
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Yuji KAWADA, Fumihiko SAITOH, Hiroshi NAGASUE, Tsutomu SATOH
  • Patent number: 10786575
    Abstract: A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ?3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: September 29, 2020
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hiromitsu Ito, Hirosato Fujii, Motoo Yamagata, Daichi Tanaka
  • Publication number: 20200289547
    Abstract: The present invention provides a composition for filling the nucleus pulposus of an intervertebral disc, the composition containing a low endotoxin monovalent metal salt of alginic acid. The composition is applied to a nucleus pulposus site of a subject, is used so as to be cured partially after application, and has fluidity when applied to the nucleus pulposus site. Accordingly, a composition for filling nucleus pulposus is provided, the composition being capable of promoting the regeneration of the nucleus pulposus of an intervertebral disc.
    Type: Application
    Filed: January 27, 2017
    Publication date: September 17, 2020
    Applicants: National University Corporation Hokkaido University, Mochida Pharmaceutical Co., Ltd
    Inventors: Hideki SUDO, Takeru TSUJIMOTO, Norimasa IWASAKI, Satoshi SHIMIZU, Mitsuko ISAJI
  • Patent number: 10758622
    Abstract: A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ?3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: September 1, 2020
    Assignee: MOCHIDA PHARMACEUTICALS CO., LTD.
    Inventors: Hiromitsu Ito, Hirosato Fujii, Motoo Yamagata
  • Publication number: 20200268931
    Abstract: Provided is a non-tubular brain damage recovery material which is used to cover and/or fill a damaged part of the brain, the brain damage recovery material including: (A) a cross-linked body with which a bioabsorbable polysaccharide having a carboxyl group in a low endotoxin molecule is covalently bonded and cross-linked with at least one crosslinking reagent selected from among a compound represented by general formula (I) and salts thereof; and (B) a bioabsorbable polymer. R1HN—(CH2)n—NHR2 (I) [in the formula, R1 and R2 each independently represent a hydrogen atom or a group represented by formula of —COCH(NH2)—CH2]4—NH2, and n represents an integer from 2 to 18]. Accordingly, provided is a medical material which can recover a damaged part of the brain.
    Type: Application
    Filed: September 13, 2017
    Publication date: August 27, 2020
    Applicants: Tazuke Kofukai, Mochida Pharmaceutical Co., Ltd.
    Inventors: Yoshihisa Suzuki, Masao TANIHARA, Mitsuko ISAJI
  • Publication number: 20200246299
    Abstract: Novel compositions comprising omega-3 fatty acids and uses thereof are disclosed.
    Type: Application
    Filed: April 20, 2020
    Publication date: August 6, 2020
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Omar Abdelfattah ABU-BAKER, Donald MACKENZIE, Rennan PAN
  • Publication number: 20200239419
    Abstract: An intermediate compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is disclosed wherein the intermediate compound is represented by formula (AM-2-RR)?(D-TA): in which p represents an integer of 0 to 4; R1 each independently represent a halogen atom, a cyano group, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a hydroxy C1-6 alkyl group, a cyanated C1-6 alkyl group, a halogenated C1-6 alkoxy group, a C1-6 alkoxy C1-6 alkyl group, a mono-/di-C2-7 alkanoyl amino group, a carboxamide group, or a C1-6 alkoxy carbonyl group; and R2a and R2b each independently represent a C1-6 alkyl group.
    Type: Application
    Filed: April 15, 2020
    Publication date: July 30, 2020
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Yuji KAWADA, Fumihiko SAITOH, Hiroshi NAGASUE
  • Patent number: 10716775
    Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: July 21, 2020
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito
  • Patent number: 10676532
    Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 9, 2020
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa
  • Patent number: 10668038
    Abstract: Novel compositions comprising omega-3 fatty acids and uses thereof are disclosed.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: June 2, 2020
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Omar Abdelfattah Abu-Baker, Donald MacKenzie, Rennan Pan
  • Patent number: 10669239
    Abstract: The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like).
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: June 2, 2020
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko Saitoh, Hiroshi Nagasue
  • Publication number: 20200069726
    Abstract: The present invention provides a ready-to-use sterile alginate aqueous solution preparation which is packed in a sealed container or an airtight container and which has storage stability, comprising: (a) a low-endotoxin monovalent metal salt of alginic acid having a weight average molecular weight of 50,000 to 400,000 by a GPC-MALS method; (b) a salt selected from a monovalent metal salt and an ammonium salt; and (c) water, wherein a concentration of the component (a) is 1.5% by mass or more, a concentration of the component (b) is 0.5 to 2% by mass, and a viscosity measured at 20° C. using a rotational viscometer is 2700 mPa·s or more, and a method of producing the same. This alginate aqueous solution preparation is a ready-to-use aqueous solution preparation of a low-endotoxin monovalent metal salt of alginic acid.
    Type: Application
    Filed: March 6, 2018
    Publication date: March 5, 2020
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shuichi ENDO, Motoi NAKAHARA
  • Patent number: 10576053
    Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: March 3, 2020
    Assignees: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Nobushige Doisaki, Shingo Arato, Takuro Fukae
  • Publication number: 20200046672
    Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 13, 2020
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hirosato FUJII, Motoo YAMAGATA
  • Publication number: 20200030367
    Abstract: The present invention has an objective of providing a novel composition for treating a fibrocartilaginous tissue injury. The present invention provides a composition for treating a fibrocartilaginous tissue injury, which is to be applied to an injured fibrocartilaginous tissue part of a target and which comprises a monovalent metal salt of alginic acid, more preferably a low endotoxin monovalent metal salt of alginic acid.
    Type: Application
    Filed: March 1, 2018
    Publication date: January 30, 2020
    Applicants: Mochida Pharmaceutical Co., Ltd, National University Corporation Hokkaido University
    Inventors: Eiji KONDO, Norimasa IWASAKI, Tomohiro ONODERA, Wooyoung KIM, Yasuyuki KAWAGUCHI
  • Patent number: 10493052
    Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: December 3, 2019
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hirosato Fujii, Motoo Yamagata
  • Publication number: 20190358186
    Abstract: A medical composition for reducing the rate of new-onset diabetes caused by administration of a statin or for inhibiting an increase in blood glucose level by administration of a statin, the composition containing at least one ingredient selected from the group consisting of icosapentaenoic acid and pharmaceutically acceptable salts or esters thereof as an inactive ingredient.
    Type: Application
    Filed: August 13, 2019
    Publication date: November 28, 2019
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Masahiko OHTA, Shinichi OIKAWA, Mitsuhiro YOKOYAMA, Hideki ORIGASA, Masunori MATSUZAKI, Yuji MATSUZAWA, Yasushi SAITO
  • Publication number: 20190337897
    Abstract: The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like).
    Type: Application
    Filed: July 17, 2019
    Publication date: November 7, 2019
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko SAITOH, Hiroshi NAGASUE
  • Patent number: 10441560
    Abstract: The disclosure provides for a method for treating a fatty liver disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic, or has normal or substantially normal biliary tract function; and administering a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E). In some cases EPA-E present may be at least 40% by weight in total of the fatty acids and their derivatives.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 15, 2019
    Assignee: Mochida Pharmaceutical Co., LTD.
    Inventors: Tsuyoshi Harada, Hideo Kanehiro, Kiyoshi Mizuguchi
  • Patent number: 10399945
    Abstract: The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like).
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: September 3, 2019
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko Saitoh, Hiroshi Nagasue